Autolus Therapeutics plc
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · London, United Kingdom
AUTL chart
What traders are saying about $AUTL
Latest postsAutolus Therapeutics plc news
- Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven (NASDAQ:AUTL)
Seeking Alpha ·
- Autolus Therapeutics: Key Questions For The Near Term
Seeking Alpha ·
- Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Yahoo Finance ·
- Autolus Therapeutics plc Estimates – NASDAQ:AUTL
TradingView ·
- All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Yahoo Finance ·
- Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Yahoo Finance ·
- AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
Yahoo Finance ·
- Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Yahoo Finance ·
- Autolus Therapeutics Q2 Earnings Call Highlights
marketbeat.com ·
- Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Yahoo Finance ·
- Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Yahoo Finance ·
- Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Yahoo Finance ·
Autolus Therapeutics plc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | – | – |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M |
| Diluted EPS | $-1.08 | $-0.86 | $-1.20 | $-1.57 |
| Total assets (year end) | $589.1M | $782.7M | $375.4M | $490.3M |
| Cash and equivalents (year end) | $104.1M | $227.4M | $239.6M | $382.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Autolus Therapeutics plc
- Ticker
- AUTL (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- London, United Kingdom
- Incorporated in
- United Kingdom
- Fiscal year end
- December 31
- SEC CIK
- 1730463
- Former names
- Autolus Therapeutics Ltd
Frequently asked questions
What exchange is Autolus Therapeutics plc listed on?
Autolus Therapeutics plc trades on the Nasdaq under the ticker symbol AUTL.
What industry is Autolus Therapeutics plc in?
Autolus Therapeutics plc is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc's business address on file with the SEC is in London, United Kingdom.
When does Autolus Therapeutics plc's fiscal year end?
Autolus Therapeutics plc's fiscal year ends on December 31.
How much revenue did Autolus Therapeutics plc report?
Autolus Therapeutics plc reported $75.4M in revenue for calendar year 2025, according to its SEC filings.